Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
"These studies represent our first glance at some of the drugs that may improve cancer treatment in coming years," said Prof Ahmad Awada, head of the medical oncology clinic at Jules Bordet Institute, Brussels, Belgium, chair of the ESMO 2012 Developmental Therapeutics track. "Today's findings highlight the ways that clinical research is working on cancer therapies that target specific molecular pathways within tumor cells and their microenvironment. At ESMO 2012 this year, interesting early reports will be presented on MEK-, MET- and HSP90 inhibitors as well as studies on drugs targeting EGFR and PI3K and agents active in ALK-positive lung cancer resistant to crizotinib. In addition, new immunotherapeutic strategies and new generations of hormonal agents will be at the menu at this year's ESMO congress."
Key selected studies include:
A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer
In a dose-escalation trial, 87% of 15 patients who received a novel androgen receptor agonist called ODM-201 experienced a PSA decrease at 12 weeks. "These early results are very promising, and such are rarely seen in these early trials. ODM-201 might be a new hormonal treatment option, and its efficacy-safety profile seems to be very promising in prostate cancer patients," said study author Dr Christophe Massard from Institute Gustave Roussy. "Unlike other anti-androgens, according to non-clinical data, ODM-201 has minimal or no brain entrance, and thus no testosterone increase in animal models. Therefore ODM-201 could be a promising new drug option for patients with metastatic or non metastatic prostate cancer. The results need to be confirmed in bigger patient population of course."
A dose-escalation study of oral selective c-Met inhibitor EMD 1214063 in patients with advanced solid tumors
The cell surface receptor tyrosine kinase c-Met is an emerging target for cancer treatment. EMD 1214063 is a highly selective, reversible and ATP-competitive c-Met inhibitor that causes growth inhibition and regression of HGF-dependent and HGF-independent tumors in pre-clinical models. This dose-escalation study is ongoing, with some preliminary evidence of clinical response being seen.
Multicenter study of the investigational drug TAK-733, an oral MEK inhibitor
Preliminary data of this trial in patients with advanced solid tumors indicate that TAK-733 is generally well tolerated and pharmacodynamically active with signs of anti-tumor activity in patients with advanced non-hematologic malignancies, say researchers.
Phase II study of HSP90 inhibitor AUY922 in patients with ALK-rearranged or EGFR-mutated advanced lung cancer
Among 121 patients with previously treated non-small cell lung cancer, activity was demonstrated in both ALK+ and EGFR-mutant patients, say investigators. Overall tumor response and progression-free survival rates observed warrant further studies, particularly among EGFR-mutant patients.Results of a first-in-human study of the ALK inhibitor LDK378 in advanced solid tumors
ESMO PERSS OFFICE | EurekAlert!
Fast-tracking T cell therapies with immune-mimicking biomaterials
16.01.2018 | Wyss Institute for Biologically Inspired Engineering at Harvard
Dengue takes low and slow approach to replication
12.01.2018 | Duke University
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
16.01.2018 | Materials Sciences
16.01.2018 | Materials Sciences
16.01.2018 | Power and Electrical Engineering